Loading stock data…
RCEL
$4.12-0.04 (-0.96%)
After Hours$4.18+0.06 (+1.46%)· Last close Jun 9
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AVITA Medical, Inc. in the Healthcare sector is trading at $4.13 with a market capitalization of $128M. Wall Street consensus targets $7.07 (3 analysts), implying a +71.2% move over the next 12 months. The stock is currently 42% below its 52-week high of $7.12, remaining 3.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +71.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$4.12
Potential Downside
0%
Whystock Fair Value$4.12
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harves...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$128.03M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.90
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
195.71%
Volume
Today's trading volume
199,898
Recent News
Undervalued Small Caps With Insider Buying Across Regions
The United States market has experienced a flat week, yet it has shown a robust 27% increase over the past year, with earnings anticipated to grow by 17% annually in the coming years. In this context of growth and stability, identifying stocks that are currently undervalued can offer potential opportunities for investors seeking to capitalize on insider confidence and regional strengths.
AVITA Medical, Inc. Q1 2026 Earnings Call Summary
Moby summary of AVITA Medical, Inc.'s Q1 2026 earnings call
AVITA Medical Inc (AVHHL) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...
AVITA Medical Inc (AVHHL) reports a 4% year-over-year revenue increase and reaffirms full-year guidance, while addressing margin pressures and cash flow challenges.
Avita Medical Q1 Earnings Call Highlights
Avita Medical (NASDAQ:RCEL) reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook as management said reimbursement conditions for its RECELL product are normalizing and demand patterns are becoming more consistent. The regenerative medicine company posted first-quarter rev
Avita Medical (RCEL) Soars 14.1%: Is Further Upside Left in the Stock?
Avita Medical (RCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.